1. Home
  2. AVB vs BIIB Comparison

AVB vs BIIB Comparison

Compare AVB & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AVB

AvalonBay Communities Inc.

HOLD

Current Price

$175.99

Market Cap

25.8B

Sector

Real Estate

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$195.93

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AVB
BIIB
Founded
1978
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.8B
24.2B
IPO Year
1994
1991

Fundamental Metrics

Financial Performance
Metric
AVB
BIIB
Price
$175.99
$195.93
Analyst Decision
Buy
Buy
Analyst Count
16
26
Target Price
$202.84
$195.13
AVG Volume (30 Days)
1.4M
1.6M
Earning Date
02-04-2026
02-06-2026
Dividend Yield
4.04%
N/A
EPS Growth
N/A
N/A
EPS
7.40
8.79
Revenue
$3,041,189,000.00
$9,890,600,000.00
Revenue This Year
$4.43
N/A
Revenue Next Year
$5.45
N/A
P/E Ratio
$23.81
$22.36
Revenue Growth
2.59
2.22
52 Week Low
$166.73
$110.04
52 Week High
$230.21
$202.41

Technical Indicators

Market Signals
Indicator
AVB
BIIB
Relative Strength Index (RSI) 48.77 64.38
Support Level $173.75 $187.20
Resistance Level $181.18 $202.41
Average True Range (ATR) 4.72 6.19
MACD 0.29 1.76
Stochastic Oscillator 58.69 81.34

Price Performance

Historical Comparison
AVB
BIIB

About AVB AvalonBay Communities Inc.

AvalonBay Communities owns a portfolio of 295 apartment communities with almost 90,000 units and is developing 20 additional properties with approximately 7,300 units. The company focuses on owning large, high-quality properties in major metropolitan areas of New England, New York/New Jersey, Washington, D.C., California, and the Pacific Northwest.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: